Andrea Botticelli

Pubblicazioni

Titolo Pubblicato in Anno
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable JOURNAL FOR IMMUNOTHERAPY OF CANCER 2019
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice JOURNAL OF TRANSLATIONAL MEDICINE 2019
Clinical Impact of Highly Purified, Whey Proteins in Patients Affected With Colorectal Cancer Undergoing Chemotherapy: Preliminary Results of a Placebo-Controlled Study 2019
Electrochemotherapy as Promising Treatment Option in Rare Recurrent Cutaneous Neoplasm of the Scalp: Case Report of an Elderly Patient CASE REPORTS IN ONCOLOGICAL MEDICINE 2019
L’immunoterapia nel tumore del polmone non a piccole cellule: ritorno al futuro RECENTI PROGRESSI IN MEDICINA 2019
Molecular detection of EMT markers in circulating tumor cells from metastatic non-small cell lung cancer patients. Potential role in clinical practice ANALYTICAL CELLULAR PATHOLOGY 2018
TK inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway CANCER IMMUNOLOGY RESEARCH 2018
Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival MEDICAL ONCOLOGY 2018
The microbiota impact. bacteria shaping immunity, disease and response to therapy TRANSLATIONAL CANCER RESEARCH 2018
The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one CANCER TREATMENT REVIEWS 2018
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? JOURNAL OF TRANSLATIONAL MEDICINE 2018
Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines ONCOTARGET 2018
Effect of nutritional support with highly purified, whey proteins for malnutrition and sarcopenia in patients affected with stage II-III colorectal or breast cancer: A blind, placebo controlled, randomized clinical trial JOURNAL OF CLINICAL ONCOLOGY 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study CANCER BIOLOGY & THERAPY 2018
Nivolumab in pretreated non-small cell lung cancer: Continuing the immunolution TRANSLATIONAL LUNG CANCER RESEARCH 2018
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab CANCER BIOLOGY & THERAPY 2018
Biliary tract cancer: current challenges and future prospects CANCER MANAGEMENT AND RESEARCH 2018
Evaluation of 5-fluorouracil degradation rate and pharmacogenetic profiling to predict toxicity following adjuvant capecitabine EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2017
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment ONCOTARGET 2017
Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes ANTICANCER RESEARCH 2017

Progetti di Ricerca

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma